Check-Cap Ltd. (CHEK)
USD 0.76
(-3.74%)
USD 0.76
(-3.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 25.01 Million USD | -44.95% |
| 2022 | 45.44 Million USD | -18.36% |
| 2021 | 55.65 Million USD | 183.42% |
| 2020 | 19.63 Million USD | 108.27% |
| 2019 | 9.42 Million USD | -38.92% |
| 2018 | 15.43 Million USD | 95.24% |
| 2017 | 7.9 Million USD | -35.7% |
| 2016 | 12.29 Million USD | -19.63% |
| 2015 | 15.29 Million USD | 96.51% |
| 2014 | 7.78 Million USD | 44.84% |
| 2013 | 5.37 Million USD | -36.73% |
| 2012 | 8.49 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 25.01 Million USD | -44.95% |
| 2023 Q2 | 33.72 Million USD | -18.37% |
| 2023 Q4 | 25.01 Million USD | -13.82% |
| 2023 Q1 | 41.31 Million USD | -9.08% |
| 2023 Q3 | 29.03 Million USD | -13.92% |
| 2022 Q2 | 54.12 Million USD | -9.17% |
| 2022 Q3 | 49.54 Million USD | -8.46% |
| 2022 Q4 | 45.44 Million USD | -8.29% |
| 2022 FY | 45.44 Million USD | -18.36% |
| 2022 Q1 | 59.59 Million USD | 7.06% |
| 2021 Q1 | 36.52 Million USD | 85.99% |
| 2021 FY | 55.65 Million USD | 183.42% |
| 2021 Q3 | 60.57 Million USD | 85.77% |
| 2021 Q4 | 55.65 Million USD | -8.12% |
| 2021 Q2 | 32.6 Million USD | -10.72% |
| 2020 FY | 19.63 Million USD | 108.27% |
| 2020 Q1 | 10.59 Million USD | 12.38% |
| 2020 Q2 | 17.87 Million USD | 68.71% |
| 2020 Q3 | 23.18 Million USD | 29.7% |
| 2020 Q4 | 19.63 Million USD | -15.3% |
| 2019 Q1 | 18.29 Million USD | 18.5% |
| 2019 FY | 9.42 Million USD | -38.92% |
| 2019 Q4 | 9.42 Million USD | -26.88% |
| 2019 Q3 | 12.89 Million USD | -19.14% |
| 2019 Q2 | 15.94 Million USD | -12.81% |
| 2018 Q4 | 15.43 Million USD | -16.54% |
| 2018 Q2 | 20.78 Million USD | 277.08% |
| 2018 Q1 | 5.51 Million USD | -30.29% |
| 2018 FY | 15.43 Million USD | 95.24% |
| 2018 Q3 | 18.49 Million USD | -11.0% |
| 2017 FY | 7.9 Million USD | -35.7% |
| 2017 Q2 | 10.1 Million USD | -1.74% |
| 2017 Q3 | 7.78 Million USD | -22.99% |
| 2017 Q1 | 10.28 Million USD | -16.38% |
| 2017 Q4 | 7.9 Million USD | 1.62% |
| 2016 Q2 | 10.72 Million USD | -16.09% |
| 2016 FY | 12.29 Million USD | -19.63% |
| 2016 Q4 | 12.29 Million USD | -14.76% |
| 2016 Q3 | 14.42 Million USD | 34.5% |
| 2016 Q1 | 12.78 Million USD | -16.45% |
| 2015 Q2 | 19.7 Million USD | -4.74% |
| 2015 Q1 | 20.68 Million USD | 165.75% |
| 2015 FY | 15.29 Million USD | 96.51% |
| 2015 Q4 | 15.29 Million USD | -11.36% |
| 2015 Q3 | 17.25 Million USD | -12.44% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 7.78 Million USD | 44.84% |
| 2014 Q2 | 3.27 Million USD | 0.0% |
| 2014 Q4 | 7.78 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 5.37 Million USD | -36.73% |
| 2013 Q3 | 5.37 Million USD | 0.0% |
| 2013 Q4 | 5.37 Million USD | 0.0% |
| 2012 FY | 8.49 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 87.327% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -83.254% |
| Aspira Women's Health Inc. | 6.26 Million USD | -299.505% |
| Biodesix, Inc. | 99.09 Million USD | 74.755% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -119.451% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -204.286% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -204.286% |
| Bionano Genomics, Inc. | 214.4 Million USD | 88.332% |
| CareDx, Inc | 484.61 Million USD | 94.838% |
| Castle Biosciences, Inc. | 477.81 Million USD | 94.764% |
| DarioHealth Corp. | 96.38 Million USD | 74.046% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.613% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 98.035% |
| Guardant Health, Inc. | 1.78 Billion USD | 98.6% |
| ICON Public Limited Company | 16.98 Billion USD | 99.853% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.233% |
| Illumina, Inc. | 10.11 Billion USD | 99.753% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -81.561% |
| iSpecimen Inc. | 15.81 Million USD | -58.144% |
| Standard BioTools Inc. | 323.06 Million USD | 92.256% |
| MDxHealth SA | 129.13 Million USD | 80.627% |
| 23andMe Holding Co. | 395.16 Million USD | 93.669% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 98.49% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 97.913% |
| Mainz Biomed B.V. | 15.4 Million USD | -62.353% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -270.395% |
| NeoGenomics, Inc. | 1.68 Billion USD | 98.512% |
| Neogen Corporation | 4.58 Billion USD | 99.454% |
| Inotiv, Inc. | 856.53 Million USD | 97.079% |
| Natera, Inc. | 1.45 Billion USD | 98.283% |
| OPKO Health, Inc. | 2.01 Billion USD | 98.756% |
| Psychemedics Corporation | 13.27 Million USD | -88.523% |
| Prenetics Global Limited | 254.17 Million USD | 90.157% |
| Prenetics Global Limited | 254.17 Million USD | 90.157% |
| Precipio, Inc. | 18.1 Million USD | -38.208% |
| Personalis, Inc. | 225.09 Million USD | 88.886% |
| RadNet, Inc. | 2.88 Billion USD | 99.133% |
| Sera Prognostics, Inc. | 95.44 Million USD | 73.788% |
| Sotera Health Company | 3.13 Billion USD | 99.201% |
| Neuronetics, Inc. | 115.83 Million USD | 78.402% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 71.236% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 71.236% |
| Trinity Biotech plc | 59.43 Million USD | 57.909% |
| Twist Bioscience Corporation | 776.4 Million USD | 96.778% |
| Exagen Inc. | 56.94 Million USD | 56.067% |